According to the latest report by IMARC Group, titled “Pharmaceutical Drug Delivery Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028,” the global pharmaceutical drug delivery market size reached US$ 1,325 Billion in 2022. Pharmaceutical drug delivery refers to the process of administering therapeutic substances to the body in order to achieve the desired pharmacological effect. It encompasses the various methods and techniques employed to ensure the safe and effective delivery of pharmaceutical drugs to specific target sites within the body. The primary goal of drug delivery systems is to enhance therapeutic outcomes while minimizing adverse effects and optimizing patient compliance. It utilizes various mechanisms to control drug release and ensure its optimal absorption and distribution. It also incorporates various technologies such as nanoparticles, liposomes, microparticles, hydrogels, or controlled-release matrices. Additionally, it can be designed to target specific tissues or cells, allowing for localized therapy, and minimizing systemic side effects.
Global Pharmaceutical Drug Delivery Market Trends:
The growing focus on personalized medicine and targeted therapies is driving the global market. Moreover, continual advancements in drug formulation and delivery technologies are further catalyzing the market. Additionally, researchers are constantly developing innovative approaches such as nanotechnology, liposomes, and microparticles to enhance drug stability, bioavailability, and controlled release, which enable the development of novel drug delivery systems that can overcome various challenges associated with traditional formulations, such as poor solubility, rapid metabolism, or short half-life, thus impelling the market. Furthermore, the increasing prevalence of chronic diseases, such as diabetes, cardiovascular disorders, and cancer, is fuelling the need for advanced drug delivery systems as these conditions often require long-term treatment with multiple medications, and optimized drug delivery methods can improve therapeutic outcomes and quality of life for patients. Other factors, including rapid urbanization, continual improvements in the healthcare sector and extensive research and development (R&D) activities conducted by key players, are also positively influencing the market. Looking forward, the market value is projected to reach US$ 1,848 Billion by 2028, expanding at a CAGR of 5.5% during 2023-2028.
- Based on the route of administration, the market has been segmented into oral, injectable, topical drug, ocular, pulmonary, implantable, transmucosal, and nasal drug deliveries.
- On the basis of the application, the market has been divided into infectious diseases, cancer, cardiovascular diseases, respiratory diseases, central nervous system disorders, autoimmune diseases, and others.
- Based on the end user, the market has been bifurcated into hospitals, ambulatory surgery centers, home care settings, diagnostic centers, and others
- Region-wise, the market has been segmented into North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa.
- The competitive landscape of the market has also been examined, with some of the key players being AbbVie Inc., Amgen Inc., AstraZeneca plc, Becton Dickinson and Company, Eli Lilly and Company, GSK plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc. and Sanofi S.A.
|Base Year of the Analysis
||Route of Administration, Application, End User, Region
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||AbbVie Inc., Amgen Inc., AstraZeneca plc, Becton Dickinson and Company, Eli Lilly and Company, GSK plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc. and Sanofi S.A.
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800